December 2022 EGRP Cancer Epidemiology News

EGRP Cancer Epidemiology News


New Reflections on Cancer Control

We are pleased to announce the 2022 Overview and Highlights! It has been a special year. We marked the 25th anniversary of the Division of Cancer Control and Population Sciences (DCCPS) and began planning how to build on that progress in the future.

The Overview and Highlights report outlines how DCCPS programs advance cancer control science to help reduce the disease burden. It also identifies six key future directions for research: health equity, data strategies, evidence-based cancer control policy research, digital health, modifiable risk factors, and climate change. These topics are already part of the research we support. However, with broad input from across the cancer control community, we recognized that immediate and intensified focus in these areas will accelerate scientific progress and increase the impact of DCCPS-sponsored research.

In collaboration with the investigator community and with colleagues and partners at the National Cancer Institute and beyond, DCCPS is committed to doing meaningful work that advances cancer control for the benefit of all. 

Learn more and download the report at https://cancercontrol.cancer.gov/overview-highlights/2022. You can also hear Dr. Katrina Goddard discuss future directions for DCCPS during the December 2022 Joint Virtual Board of Scientific Advisors/National Cancer Advisory Board Meeting. To listen to Dr. Goddard’s presentation, go to the 2:22:30 timestamp of the videocast from December 6, 2022.

Funding Opportunities

  • RFA-RM-23-003, Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03, Clinical Trial Not Allowed)
  • RFA-CA-23-020, NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1, Clinical Trial Required)
  • RFA-CA-23-021, NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1, Clinical Trial Required)
  • RFA-CA-23-022, NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1, Clinical Trial Required)
  • RFA-CA-23-002, Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61, Clinical Trial Not Allowed)
  • RFA-CA-23-003, Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • RFA-CA-23-004, Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61, Clinical Trial Not Allowed)
  • RFA-CA-23-005, Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • RFA-CA-23-006, Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01, Clinical Trial Optional)
  • RFA-CA-23-007, Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, Clinical Trial Optional)
  • RFA-CA-23-008, Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54, Clinical Trials Optional)
  • RFA-CA-23-009, Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01, Clinical Trial Optional)
  • RFA-CA-23-010, Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50, Clinical Trial Optional)
  • RFA-CA-23-011, Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C, Clinical Trial Optional)
  • PAR-22-256, Pragmatic Trials Across the Cancer Control Continuum (UG3/UH3, Clinical Trial Required)
  • PAR-23-055, Co-infection and Cancer (R01, Clinical Trial Not Allowed)
  • PAR-23-056, Co-infection and Cancer (R21, Clinical Trial Not Allowed)
  • PAR-23-058, NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03, Clinical Trial Optional)
  • PAR-23-042, Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01, Clinical Trial Optional)
  • PAR-23-043, Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R61/R33, Clinical Trial Required)
  • NOT-OD-23-018, Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp, Clinical Trial Optional)
  • NOT-OD-23-029, NOSI: Research on Gender Measurement (Admin Supp Clinical Trial Optional)
  • NOT-OD-23-002, NOSI: Administrative Supplements to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility (DEIA) Mentorship
  • NOT-OD-23-031, NOSI: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars
  • NOT-OD-23-032, NOSI: Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards
  • NOT-PM-23-001, Notice of Future Research Opportunity Announcement for All of Us Research Participant and Partner Services Center

Requests for Information

  • NOT-CA-23-007, Soliciting Input on the Use and Reuse of Cancer Metabolomics Data (responses requested by December 23, 2022)
  • NOT-CA-23-011, Challenges and Opportunities Associated with Multidimensional Tumor Atlases (responses requested by January 7, 2023)
  • NOT-CA-23-014, Priorities for Precision Cancer Prevention of Pancreatic and Liver Cancer Science at NCI (responses requested by January 20, 2023)
  • NOT-CA-23-016, Priorities for Cancer Prevention and Symptom Management Science at NCI (responses requested by January 20, 2023)
  • NOT-OD-23-034: Proposed Simplified Review Framework for NIH Research Project Grant Applications (responses requested by March 10, 2023)

Grants Policy Announcements

  • NOT-OD-23-035, Announcing New Inbox for Inquiries Related to Federal Financial Reports and Financial Closeout
  • NOT-OD-23-022, OMB Single Audit Extension for Recipients in Major Disaster Areas (Alaska, Florida, South Carolina, North Carolina, Puerto Rico)

Training Opportunities

NIH/NCI News and Blog Posts

Stay Connected

Subscribe for Updates

Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730